What is the Effect of Riskshaw Noise on its Driver?

Journal of the Pakistan Medical Association

Volumn 50, Issue 4, 2000, Pages 124-130

  Merchant, Anwar T ^a   Lalani, Irfan ^a   Afridi, Zahid H ^a   Latif, Nida ^a   Malik, Talha A ^a   Merchant, Shehazad S ^a   Momin, Inayat A ^a   Moizuddin, Sonia S ^a   Motiei, Arashk ^a   Motiwala, Shaheen ^a   Munir, Asma ^a   Sethi, Ayesha K ^a  

^a AGA KHAN UNIVERSITY MEDICAL COLLEGE   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CAR DRIVING; COMPARATIVE STUDY; CONFIDENCE INTERVAL; HEALTH SURVEY; HUMAN; INCIDENCE; INDUSTRIAL NOISE; MALE; MOTOR VEHICLE; NOISE INJURY; PAKISTAN; QUESTIONNAIRE; RISK FACTOR;

ADULT; AUTOMOBILE DRIVING; CONFIDENCE INTERVALS; HEALTH SURVEYS; HEARING LOSS, NOISE-INDUCED; HUMANS; INCIDENCE; MALE; NOISE, OCCUPATIONAL; OFF-ROAD MOTOR VEHICLES; PAKISTAN; QUESTIONNAIRES; RISK FACTORS;

EID: 0034168740     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. McAlpine D, Compston ND, Acheson ED Multiple sclerosis: a reappraisal, 2nd ed. London: Churchill Livingstone, 1972:214.
2. Ormerod IEC, Miller DH, McDonald WI, et al. The role of MRI in the assessment of MS and isolated neurological lesions: a quantitative study Brain, 1987;110:1579-1616.
3. Miller DH. MRI: Sensitive and safe in diagnosing MS. MRI Decisions, 1988;2:17-24.
4. McFarland H, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis Ann. Neurol., 1992;32:758-66.
5. Smith ME, Stone LA, Albert PA, et al. Clinical worsening in MS associated with increased frequency and area of gadopentate dimeglumine enhancing magnetic resonance imaging lesions. Ann. Neurol., 1993;33:480-89.
6. Gonzalez-Scarano F, Grossman RI, Galetta S, et al. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. Ann. Neurol., 1987;21:300-6.
7. Osborn AG: Diagnostic Neuroradiology. St. Louis, Mosby, 1994.
8. Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone versus ACTH in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology, 1986;36:238-43.
9. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: I. Clinical effects. J. neurol. Neurosurg Psychiatry, 1987;50:511-16.
10. Burnham JA, Wright RR, Dreisbach J. et al. The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology, 1991;41:1349-54.
11. Trotter JL, Garvey WF. Prolonged effects of large-dose methyprednisolone infusion in multiple sclerosis Neurology, 180;30:702-8.
12. Kermode AG, Tofts PS, Thompson AJ, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology, 1990;40:229-35.
13. Miller DH, Thompson AJ, Morrisey SP, et al. High-dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J. Neurol. Neurosurg. Psychiatry. 1992;55:450-53.
14. Capra R. Gadolinium-pentetic acid MRI in patients with relapsing-remitting MS. Arch. Neurol., 1992;49:687-89.